Abiopharma

🔍 PADGETT BARRY L. (Executive)

Company: SentinelOne, Inc. (S)

Report Date: 2026-03-23

Detailed Transactions and Holdings:

• Acquired 92,662 shares of Class A Common Stock (Direct)
  Date: 2026-03-23 | Code: A | equity_swap_involved: 0 | shares_owned_after: 675,871.00 | transaction_form_type: 4 | Footnotes: F1, F3
• Sold 32,221 shares of Class A Common Stock at $13.37 per share (Direct)
  Date: 2026-03-25 | Code: S | equity_swap_involved: 0 | shares_owned_after: 643,650.00 | transaction_form_type: 4 | Footnotes: F4, F3

Footnotes:

• F1: The reported transaction represents the certification of achievement of the first of four tranches of a performance-based restricted stock unit award granted to the reporting person by the Issuer's compensation committee on April 15, 2025 (the "2025 PRSU Award"). Vesting of each tranche of the 2025 PRSU Award is based on the achievement of pre-determined corporate performance milestones and is subject to the reporting person's continued service through the certification date of achievement of the relevant tranche.
• F2: On March 23, 2026 (the "Certification Date"), the Issuer's compensation committee certified achievement of the first tranche of the 2025 PRSU Award, resulting in one-fourth of the 2025 PRSU Award becoming earned at 90.2% of the target amount granted. The performance restricted stock units comprising the first tranche of the 2025 PRSU Award so earned are fully vested and may be settled for shares of the Issuer's Class A common stock on the Certification Date.
• F3: Certain of the shares are subject to forfeiture to the Issuer if underlying vesting conditions are not met.
• F4: The sale reported on this Form 4 represents an Issuer mandated sale by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of performance-based Restricted Stock Units, and it does not represent a discretionary trade by the Reporting Person. Pursuant to the Issuer's equity incentive plan, an award recipient's tax withholding obligations must be funded by a "sell to cover" transaction.